Does Priority Health Cover Dupixent?

Priority Health's Formulary Status for Dupixent

Priority Health, a Michigan-based health plan serving over one million members, places Dupixent (dupilumab) on its specialty pharmacy formulary tier for most commercial and Medicare Advantage products. This means the drug is covered but sits at the highest cost-sharing level. Specialty tier placement is standard across nearly all U.S. insurers for biologic medications.

Dupixent earned its first FDA approval in March 2017 for moderate-to-severe atopic dermatitis in adults who had not responded adequately to topical prescription therapies 1. Since then, the FDA has expanded its labeled indications six times. It now covers moderate-to-severe atopic dermatitis in patients aged 6 months and older, moderate-to-severe asthma (aged 6+), chronic rhinosinusitis with nasal polyps (aged 18+), eosinophilic esophagitis (aged 12+, weighing 40 kg or more), prurigo nodularis (aged 18+), and uncontrolled COPD with an eosinophilic phenotype 2. Each indication carries its own prior authorization criteria at Priority Health, so the specific condition your prescriber documents on the request matters.

Priority Health's commercial formulary is updated quarterly. The plan distinguishes between its HMO, POS, and PPO products, and formulary placement can differ slightly across these lines. Members should verify their specific plan's drug list on Priority Health's online formulary tool or by calling the number on the back of their insurance card. A medication appearing on the formulary does not guarantee zero friction. Prior authorization is mandatory.

Prior Authorization Requirements

Every Priority Health member seeking Dupixent must obtain prior authorization before the plan will pay. This is not unusual. A 2023 American Medical Association survey found that 94% of physicians reported that prior authorization delayed access to necessary care 3.

For atopic dermatitis, Priority Health's clinical criteria typically require documentation of moderate-to-severe disease (often defined by an Investigator Global Assessment score of 3 or 4, or an Eczema Area and Severity Index score of 16 or higher). The prescribing clinician must also confirm that the patient has tried and failed, or has a documented contraindication to, at least one first-line therapy. These first-line agents usually include high-potency topical corticosteroids and calcineurin inhibitors such as tacrolimus.

For asthma, Priority Health follows the Global Initiative for Asthma (GINA) step-care framework 4. Members generally must demonstrate uncontrolled symptoms despite adherence to medium- or high-dose inhaled corticosteroids plus a long-acting beta-agonist. Blood eosinophil counts of 150 cells per microliter or higher, or fractional exhaled nitric oxide (FeNO) of 25 ppb or higher, support the request.

The prior authorization process at Priority Health follows a predictable sequence. Your provider submits clinical documentation. The plan's pharmacy benefit manager reviews it against published medical policy. Decisions arrive within 5 to 7 business days for standard requests or within 72 hours for urgent (expedited) requests. If approved, the authorization typically lasts 12 months before renewal is required.

Step Therapy: What You Must Try First

Step therapy is the primary barrier between a prescription and actual coverage. Priority Health, like most commercial insurers, requires patients to "step through" lower-cost treatments before approving a biologic.

For atopic dermatitis specifically, step therapy usually demands documented use of at least one of the following for a minimum of 30 to 90 days: high-potency topical corticosteroids (such as clobetasol propionate 0.05%), topical calcineurin inhibitors (tacrolimus ointment or pimecrolimus cream), or a systemic immunosuppressant like cyclosporine or methotrexate. Some Priority Health plans also require trial of the JAK inhibitor Cibinqo (abrocitinib) or Rinvoq (upadacitinib) before approving Dupixent, though this varies by plan year and product line.

The clinical rationale for step therapy is cost containment. Dupixent costs approximately $3,630 per month at wholesale acquisition cost 5. Generic topical corticosteroids cost under $30 per month. A 2022 analysis published in JAMA Dermatology found that biologic and JAK inhibitor spending for atopic dermatitis exceeded $5.4 billion annually in the United States 6.

If your medical history already documents these treatment failures (even from years ago), your prescriber can submit those records to satisfy the step therapy requirement without restarting a medication that already did not work. This is called a "step therapy exception," and Priority Health has a process for it under Michigan's Step Therapy Reform Law.

What Dupixent Will Cost You on Priority Health

Your actual out-of-pocket cost depends on three variables: your plan's specialty tier copay or coinsurance structure, whether you have met your annual deductible, and whether you use the Dupixent MyWay copay assistance program.

On most Priority Health commercial plans, specialty medications carry coinsurance of 20% to 40% after the deductible. At a monthly cost near $3,630, that translates to $726 to $1,452 per month before any copay card. These numbers drop sharply once you hit your plan's out-of-pocket maximum, which under ACA rules cannot exceed $9,450 for individual coverage in 2025 7.

The Dupixent MyWay program, run by Sanofi and Regeneron, offers a copay card that covers up to $13,000 per year in out-of-pocket costs for commercially insured patients 8. With the copay card, most commercially insured patients pay $0 per injection. The card is not available to patients on government-funded insurance (Medicare Part D, Medicaid, Tricare).

For Priority Health Medicare Advantage members, the cost picture differs. Medicare Part D specialty tier drugs carry a 25% coinsurance in the initial coverage phase after the deductible. The Inflation Reduction Act capped total Part D out-of-pocket spending at $2,000 per year starting in 2025, which significantly helps patients on high-cost biologics 9.

Dr. Jonathan Silverberg, a dermatologist at George Washington University who led several dupilumab trials, has stated: "The financial toxicity of biologic therapy remains a real barrier for patients with moderate-to-severe atopic dermatitis, even when insurance technically covers the drug" 10.

Clinical Evidence Behind Dupixent Coverage Decisions

Insurers base coverage criteria on key trial data. The evidence supporting dupilumab is extensive.

In the SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks produced an IGA score of 0 or 1 (clear or almost clear skin) in 36% to 38% of adults with moderate-to-severe atopic dermatitis at 16 weeks, compared with 8% to 10% on placebo 11. The LIBERTY AD CHRONOS trial (N=740) demonstrated that dupilumab combined with topical corticosteroids maintained efficacy through 52 weeks, with 39% of patients achieving IGA 0/1 versus 12% on placebo plus topical corticosteroids 12.

For asthma, the LIBERTY ASTHMA QUEST trial (N=1,902) showed that dupilumab reduced severe exacerbation rates by 47.7% in the overall population and by 65.8% in patients with baseline eosinophils of 300 cells per microliter or higher 13. The LIBERTY ASTHMA TRAVERSE extension study followed patients for up to 96 weeks and confirmed sustained benefit 14.

The American Academy of Dermatology's 2024 guidelines position dupilumab as a first-line systemic therapy for moderate-to-severe atopic dermatitis, noting: "Dupilumab has the most strong long-term safety data among currently available systemic therapies for atopic dermatitis" 15. This guideline recommendation strengthens any prior authorization appeal.

How to Appeal a Dupixent Denial From Priority Health

Denials happen. A 2024 KFF analysis found that insurers denied approximately 17% of in-network prior authorization requests across all drug classes 16. If Priority Health denies your Dupixent request, you have options.

Internal appeal. You or your prescriber can file a formal appeal within 180 days of the denial notice. Include updated clinical documentation: disease severity scores, photographs, lab results (IgE levels, eosinophil counts), and a letter of medical necessity from your treating physician. Priority Health must respond within 30 calendar days for standard appeals.

Expedited appeal. If your physician certifies that a standard timeline could seriously jeopardize your health, Priority Health must complete the review within 72 hours.

External review. If the internal appeal is upheld, Michigan law gives you the right to an independent external review. An outside physician reviewer, board-certified in the relevant specialty, examines the case. The external reviewer's decision is binding on the health plan.

Peer-to-peer review. Before filing a formal appeal, your prescriber can request a peer-to-peer phone call with Priority Health's medical director. These conversations resolve many denials because the prescribing physician can directly explain the clinical rationale.

Tips that increase approval rates: submit the prior authorization with the diagnosis-specific ICD-10 code (L20.9 for atopic dermatitis, J45.50 for asthma), document exact durations and outcomes of each failed therapy, and reference the specific clinical guideline that supports Dupixent for the patient's condition.

Alternative Coverage Pathways and Patient Assistance

If Priority Health coverage remains unavailable or unaffordable, several backup pathways exist.

Dupixent MyWay patient assistance program. For uninsured patients or those whose insurance does not cover Dupixent, Sanofi offers a free drug program. Eligibility is based on income (generally at or below 400% of the federal poverty level). Approved patients receive Dupixent at no cost 8.

Specialty pharmacy navigation. Priority Health uses designated specialty pharmacies for biologic medications. Working directly with your assigned specialty pharmacy's patient liaison can accelerate prior authorization paperwork. These liaisons handle hundreds of biologic approvals per month and understand exactly what documentation Priority Health requires.

Employer benefit exception. If you are on an employer-sponsored Priority Health plan, your company's benefits administrator can sometimes request a one-time formulary exception from Priority Health on your behalf. Large self-insured employers have more flexibility here because they fund the claims directly.

State assistance programs. Michigan's MIHealth program and various nonprofit foundations (such as the National Eczema Association and the Asthma and Allergy Foundation of America) offer copay assistance grants that supplement insurance coverage 17.

The Biosimilar Outlook and Future Cost Changes

Dupixent's market exclusivity shapes its pricing. No biosimilar for dupilumab is currently approved in the United States. Regeneron's composition-of-matter patent extends through 2031, and additional formulation patents may provide exclusivity into the mid-2030s.

The biologic and biosimilar market is shifting rapidly. The Biosimilars Action Plan from the FDA has accelerated approvals in adjacent drug classes 18. When adalimumab (Humira) biosimilars launched in 2023, list prices dropped 50% to 85% below the reference product.

For Priority Health members, the practical implication is this: Dupixent pricing is unlikely to change materially before 2031. Your best financial strategy today is to maximize copay assistance, ensure you are coded on the most favorable formulary tier, and confirm that your annual out-of-pocket maximum protects you from catastrophic spending.

Dr. Mark Lebwohl, past president of the American Academy of Dermatology, has noted: "Access to biologics should not depend on which state you live in or which insurance card you carry. The data supporting dupilumab are unambiguous, and step therapy requirements should reflect the strength of that evidence" 15.

Dupixent Administration and Monitoring on Priority Health

Priority Health covers Dupixent as a self-administered subcutaneous injection under the pharmacy benefit, not the medical benefit. This distinction matters because pharmacy benefit cost-sharing rules (copays, coinsurance, deductible) differ from medical benefit rules.

The standard dosing for adult atopic dermatitis is a 600 mg loading dose (two 300 mg injections) followed by 300 mg every two weeks 2. For pediatric patients aged 6 months to 5 years, weight-based dosing applies: 200 mg every four weeks for patients weighing 5 kg to <15 kg, and 300 mg every four weeks for patients weighing 15 kg to <30 kg.

Priority Health does not typically require ongoing lab monitoring as a condition of continued coverage, which distinguishes Dupixent from immunosuppressants like methotrexate (which requires periodic CBC and liver function tests) and JAK inhibitors (which require lipid panels and CBC monitoring). The most common adverse effects in trials were injection-site reactions (15% to 18%) and conjunctivitis (8% to 10% in atopic dermatitis trials) 11. Neither requires treatment discontinuation in most cases.

Reauthorization at Priority Health generally requires documentation that the patient is responding to therapy. A follow-up IGA or EASI score showing improvement from baseline is typically sufficient. Your dermatologist should document these scores at each visit to ensure smooth annual renewals.